Oculis Holding AG (NASDAQ:OCS) Stock Has Consensus Price Target of $38.89 According to Analysts

Key Points

• Analysts have a “Moderate Buy” consensus on Oculis, with nine buys and one sell among ten analysts and an average 12-month price target of $38.89.
• Oculis shares opened at $7.49, well below their 52-week high of $34.47; analyst price targets vary, including recent targets of $20, $39 and $40.
• The company reported quarterly adjusted earnings per share of ($0.37), better than the consensus estimate of ($0.47), but revenue was just $0.01 million versus an expected $0.26 million.

Oculis Holding AG (NASDAQ:OCS - Get Free Report) has been assigned an average rating of "Moderate Buy" from the ten analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and nine have assigned a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $38.89.

A number of equities analysts have weighed in on OCS shares. Guggenheim dropped their target price on shares of Oculis to $40.00 and set a "buy" rating for the company in a research note on Wednesday. Wall Street Zen raised Oculis from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 8th. JPMorgan Chase & Co. cut their target price on Oculis from $23.00 to $20.00 and set an "overweight" rating for the company in a research note on Friday, August 14th. HC Wainwright reiterated a "buy" rating and issued a $39.00 price target on shares of Oculis in a research note on Wednesday, October 21st. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Oculis in a research report on Thursday, October 15th.

Oculis Stock Performance

Shares of OCS stock opened at $7.49 on Friday. Oculis has a 52-week low of $6.78 and a 52-week high of $34.47. The firm has a market cap of $434.27 million, a price-to-earnings ratio of -4.38 and a beta of 0.67. The company's 50 day moving average is $9.20 and its 200 day moving average is $18.35. The company has a quick ratio of 8.35, a current ratio of 8.35 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS - Get Free Report) last issued its earnings results on Tuesday, November 3rd. The company reported ($0.37) EPS for the quarter, topping analysts' consensus estimates of ($0.47) by $0.10. Oculis had a negative net margin of 6,777.18% and a negative return on equity of 42.61%. The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.26 million. On average, sell-side analysts anticipate that Oculis will post -1.83 EPS for the current fiscal year.

Institutional Investors Weigh In On Oculis

A number of large investors have recently bought and sold shares of OCS. Alps Advisors Inc. increased its holdings in shares of Oculis by 40.7% in the third quarter. Alps Advisors Inc. now owns 81,619 shares of the company's stock valued at $762,000 after buying an additional 23,600 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Oculis in the third quarter valued at approximately $74,000. Squarepoint Ops LLC raised its stake in shares of Oculis by 326.4% in the second quarter. Squarepoint Ops LLC now owns 61,605 shares of the company's stock worth $854,000 after purchasing an additional 47,158 shares during the last quarter. Braidwell LP bought a new position in Oculis in the 2nd quarter valued at $11,570,000. Finally, Bank of America Corp DE grew its position in shares of Oculis by 9.1% in the 1st quarter. Bank of America Corp DE now owns 69,764 shares of the company's stock worth $1,855,000 after buying an additional 5,813 shares during the last quarter. Institutional investors and hedge funds own 22.30% of the company's stock.

About Oculis

Oculis is a global biopharmaceutical company focused on developing innovative treatments for eye diseases. The company's research is centered on therapies that can be administered directly to the eye, including topical ophthalmic formulations and other approaches designed to improve drug delivery, efficacy, and patient convenience.

Oculis has developed a pipeline addressing ophthalmic conditions such as retinal diseases, diabetic macular edema, dry eye disease, and other disorders that can impair vision.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.